BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang J, Ma Y, Luo Q, Liang Z, Lu P, Song F, Zhang Z, Zhou T, Zhang J. Improving the solubility of vorinostat using cyclodextrin inclusion complexes: The physicochemical characteristics, corneal permeability and ocular pharmacokinetics of the drug after topical application. Eur J Pharm Sci 2022;168:106078. [PMID: 34838620 DOI: 10.1016/j.ejps.2021.106078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Qiu Q, yang L, Feng Y, Zhu Z, Li N, Zheng L, Sun Y, Pan C, Qiu H, Cui X, He W, Wang F, Yi Y, Tang M, Yang Z, Yang Y, Li Z, Chen L, Hu Y. HDAC I/IIb selective inhibitor Purinostat Mesylate combined with GLS1 inhibition effectively eliminates CML stem cells. Bioactive Materials 2023;21:483-498. [DOI: 10.1016/j.bioactmat.2022.08.006] [Reference Citation Analysis]
2 Wang C, Yan T, Yan T, Wang Z. Fabrication of Hesperetin/hydroxypropyl-β-cyclodextrin Complex Nanoparticles for Enhancement of Bioactivity Using Supercritical Antisolvent Technology. Journal of Molecular Structure 2023. [DOI: 10.1016/j.molstruc.2023.134947] [Reference Citation Analysis]
3 Zhang R, Yang J, Luo Q, Shi J, Xu H, Zhang J. Preparation and in vitro and in vivo evaluation of an isoliquiritigenin-loaded ophthalmic nanoemulsion for the treatment of corneal neovascularization. Drug Deliv 2022;29:2217-33. [PMID: 35815765 DOI: 10.1080/10717544.2022.2096714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]